Trial Profile

A Phase II Study of Capecitabine and Lapatinib in Squamous Cell Carcinoma of the Head and Neck

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 31 Mar 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Capecitabine (Primary) ; Lapatinib (Primary)
Indications Head and neck cancer; Squamous cell cancer
Focus Therapeutic Use

Most Recent Events

28 Aug 2018 Status changed from active, no longer recruiting to completed.
24 Jan 2017 Planned primary completion date changed from 1 Oct 2013 to 1 Mar 2017.
19 May 2016 Primary endpoint has been met. (Overall survival), as per an article published in the Cancer.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com